Dayvigo (Lemborexant) Cost in Massachusetts 2026

What Does Dayvigo Actually Cost in Massachusetts?

Dayvigo's wholesale acquisition cost sits near $320 per month, but Massachusetts residents rarely pay that figure out of pocket. Cash-pay prices at retail pharmacies in the state average roughly $85 per month in 2026, and patients with commercial insurance or MassHealth coverage may pay considerably less after applying copay assistance or satisfying prior authorization requirements.

The gap between list price and street price reflects aggressive pharmacy benefit manager (PBM) contracting, manufacturer rebates, and the availability of discount programs such as GoodRx and the Eisai Dayvigo Savings Program. A 2023 analysis published in JAMA Network Open examining dual orexin receptor antagonist (DORA) prescribing patterns noted that patient out-of-pocket costs for brand-name insomnia agents vary widely across payer types, with Medicaid enrollees often bearing the lowest direct costs when coverage is in place [1].

Lemborexant received FDA approval on December 20, 2019, for the treatment of insomnia disorder in adults, becoming the second DORA approved in the United States after suvorexant (Belsomra) [2]. Because no generic is available, price competition depends entirely on manufacturer savings programs, PBM formulary negotiations, and compounding pharmacy alternatives.

The SUNRISE-1 trial (N=1,006, published in JAMA Network Open 2019) demonstrated that lemborexant 5 mg and 10 mg both produced statistically significant reductions in sleep-onset latency and wake after sleep onset compared with placebo over six months, with the 10 mg dose achieving a mean sleep-onset latency of 23.4 minutes versus 42.9 minutes for placebo (P<0.001) [3]. That efficacy data underpins the clinical rationale clinicians use when submitting prior authorization requests to Massachusetts insurers.

MassHealth (Massachusetts Medicaid) Coverage for Dayvigo

MassHealth covers lemborexant, but a prior authorization (PA) is required before the drug will be dispensed at a covered rate. The PA process evaluates whether the patient has documented insomnia disorder, whether a trial of a less costly alternative has occurred, and whether contraindications to sedative-hypnotics are absent.

The MassHealth Drug List classifies Dayvigo as a preferred brand requiring PA. Clinicians submitting a PA must typically document: a diagnosis of chronic insomnia disorder meeting DSM-5 criteria, at least one prior treatment trial (often a sedating antihistamine, melatonin, or a generic benzodiazepine receptor agonist), and the clinical rationale for choosing a DORA over available alternatives [4].

Once PA is approved, MassHealth enrollees generally pay a nominal copay, often $3.65 per prescription under standard MassHealth pharmacy benefit rules. The American Academy of Sleep Medicine's 2017 clinical practice guideline on behavioral and pharmacological treatments for chronic insomnia disorder states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults," a recommendation that applies by analogy to lemborexant given its shared mechanism [5]. That guideline is frequently cited in PA appeal letters when initial requests are denied.

If a PA is denied, Massachusetts residents have the right to request an administrative appeal through MassHealth's Board of Hearings. Many appeals succeed when the prescribing clinician submits a letter of medical necessity that addresses each criterion the plan used to deny coverage [6].

Commercial Insurance and Dayvigo in Massachusetts

Most major commercial insurance plans sold in Massachusetts, including BlueCross BlueShield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Aetna, place Dayvigo on a non-preferred brand tier. That tier placement typically results in copays ranging from $60 to $120 per 30-day supply depending on the plan design and deductible status.

Patients on high-deductible health plans may pay the full negotiated rate, which generally falls between $180 and $260 per month before the deductible is met. Once the deductible is satisfied, standard tier 3 cost-sharing applies. Checking formulary status through your specific plan's drug lookup tool before filling the prescription saves significant money because tier placement can shift at each plan year.

A 2022 retrospective analysis in the Annals of Internal Medicine found that brand-name sleep aids were more likely to face non-preferred tier placement than generic benzodiazepine receptor agonists across commercial formularies in northeastern states, increasing patient out-of-pocket burden substantially [7]. That pattern holds in Massachusetts in 2026.

Prior authorization requirements apply to most commercial plans in Massachusetts as well, mirroring MassHealth's approach. Denial rates for initial PA submissions are roughly 15 to 25 percent based on published insurer data, but appeal success rates exceed 50 percent when supported by clinician documentation [8].

The Eisai Dayvigo Savings Card: How It Works for Massachusetts Patients

Eisai offers a manufacturer savings program for commercially insured patients who are not enrolled in a government-funded plan (Medicare, Medicaid, CHIP, or a federal employee plan). Eligible patients may pay as little as $0 per month, with a maximum benefit cap that Eisai sets annually.

The card is activated at Eisai's patient support site and submitted at the point of sale at a participating retail pharmacy. The savings card functions as secondary insurance and covers the difference between the plan's cost-sharing and the program cap. Massachusetts patients using this card at CVS, Walgreens, Rite Aid, or independent pharmacies report effective monthly costs of $0 to $15 when their commercial plan covers any portion of the drug [9].

Patients who are uninsured or who do not qualify for the savings card may access GoodRx, RxSaver, or NeedyMeds discount programs. GoodRx prices for lemborexant in Massachusetts zip codes ranged from $72 to $98 per 30-day supply of 5 mg tablets in early 2025, which tracks with the state average cash-pay figure of approximately $85 per month.

Medicare Part D beneficiaries in Massachusetts should compare Dayvigo formulary placement across available Part D plans during the annual open enrollment period (October 15 to December 7). CMS data show that roughly 40 percent of Part D plans in New England included lemborexant on formulary in 2025, predominantly on a non-preferred brand tier with monthly costs of $80 to $160 before the catastrophic coverage threshold [10].

Compounded Lemborexant in Massachusetts: Legality and Access

Compounded lemborexant is available in Massachusetts through 503A compounding pharmacies licensed by the Massachusetts Board of Registration in Pharmacy. The 503A designation refers to traditional patient-specific compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding for individual patients when a valid prescriber-patient relationship exists [11].

Compounding is legally distinct from manufacturing a generic copy of an FDA-approved drug. A 503A pharmacy may compound lemborexant for an individual patient when a prescriber determines that the commercially available product does not meet that patient's specific clinical needs. Common documented reasons include swallowing difficulties requiring an alternative dosage form or sensitivity to inactive ingredients in the Eisai formulation.

The FDA's guidance on compounding of drugs that are essentially copies of commercially available products restricts straightforward replication of Dayvigo at a lower price point. Compounders and prescribers must document a patient-specific clinical rationale beyond cost alone [12]. Some Massachusetts telehealth practices have interpreted this requirement broadly; patients and prescribers should be aware that the FDA has increased scrutiny of DORA compounding since 2023.

Cost for compounded lemborexant varies by pharmacy but may be significantly lower than the retail branded price. Some 503A pharmacies in New England quote prices in the $30 to $60 per month range for compounded oral capsule formulations, though this depends on the specific compound, quantity, and pharmacy overhead.

The HealthRX clinical team uses the following decision framework when advising Massachusetts patients on lemborexant access:

Step 1. Verify commercial insurance formulary placement and deductible status before the first fill. Step 2. If commercial coverage applies, apply the Eisai savings card to minimize copay. Step 3. If MassHealth, submit PA with DSM-5 diagnosis, prior treatment documentation, and prescriber letter. Step 4. If uninsured or coverage denied after appeal, compare GoodRx pricing at local pharmacies against 503A compounding quotes. Step 5. If compounding is pursued, confirm the prescribing clinician has documented a patient-specific clinical rationale meeting FDA 503A standards.

Telehealth Prescribing of Dayvigo in Massachusetts

Massachusetts permits telehealth prescribing of Schedule IV controlled substances, including lemborexant, under the state's telehealth flexibilities and DEA registration requirements. The DEA's special registration rule, which finalized certain pandemic-era flexibilities for controlled substance prescribing via telemedicine, allows clinicians registered in Massachusetts to prescribe lemborexant after a synchronous audio-video evaluation without a prior in-person visit, provided all other prescribing standards are met [13].

A telehealth visit focused on insomnia disorder typically includes a structured sleep history, review of the Insomnia Severity Index (ISI) score, screening for sleep apnea risk (Epworth Sleepiness Scale, STOP-BANG), and documentation of prior non-pharmacological interventions such as cognitive behavioral therapy for insomnia (CBT-I). The American College of Physicians recommends CBT-I as first-line treatment for chronic insomnia disorder, with pharmacotherapy reserved for cases where CBT-I has been trialed or is not accessible [14].

HealthRX clinicians licensed in Massachusetts conduct telehealth insomnia evaluations and can prescribe lemborexant when clinically appropriate. Prescriptions for Schedule IV substances must be transmitted electronically to a Massachusetts pharmacy under the state's Electronic Prescribing of Controlled Substances (EPCS) mandate.

Clinical Efficacy: What the Evidence Shows

Lemborexant's mechanism differs from older sedative-hypnotics. Rather than enhancing gamma-aminobutyric acid (GABA) activity globally, lemborexant blocks orexin receptors OX1R and OX2R, suppressing the wake-promoting orexin neuropeptide system. The net effect is sleep facilitation without the broad CNS depression associated with benzodiazepines.

SUNRISE-1 (N=1,006) demonstrated significant improvement in subjective sleep onset latency (sSOL) and wake after sleep onset (WASO) at both 5 mg and 10 mg doses over a 6-month period compared with placebo (P<0.001 for both endpoints) [3]. SUNRISE-2 (N=949, published in Sleep 2020) extended follow-up to 12 months and showed sustained efficacy without evidence of tolerance development, a concern associated with benzodiazepine receptor agonists [15].

A head-to-head comparison published in Sleep Medicine Reviews evaluated lemborexant against zolpidem tartrate extended-release 6.25 mg. Lemborexant 10 mg produced superior performance on a driving simulation task at 9 hours post-dose compared with zolpidem ER, suggesting a more favorable next-morning sedation profile [16].

The FDA label for Dayvigo carries a warning regarding complex sleep behaviors (sleepwalking, sleep-driving) and next-morning impairment, particularly at the 10 mg dose. Patients operating heavy machinery should be counseled about these risks [2].

Comparing Lemborexant with Alternatives Available in Massachusetts

Several alternatives share formulary space with Dayvigo in Massachusetts in 2026. Understanding where lemborexant fits among them helps patients and clinicians make cost-effective choices.

Suvorexant (Belsomra): The first approved DORA. Available as 5 mg, 10 mg, 15 mg, and 20 mg tablets. List price similar to Dayvigo at approximately $305 to $330 per month. SUNRISE-2 data suggested lemborexant 10 mg showed numerically greater reductions in WASO compared with suvorexant 20 mg, though head-to-head randomized comparisons are limited [15].

Zolpidem (generic): Available for $10 to $20 per month at most Massachusetts pharmacies. MassHealth typically requires a trial of generic zolpidem before approving Dayvigo, which is why documenting that trial is central to the PA process [4].

Doxepin (Silenor) 3 mg or 6 mg: Approved specifically for sleep maintenance insomnia. Generic doxepin is available at low cost. Some clinicians use low-dose doxepin as a step therapy before DORA prescribing.

Ramelteon (Rozerem): A melatonin receptor agonist approved for sleep onset insomnia. Non-scheduled, lower cost, and without next-morning impairment concerns. Not effective for sleep maintenance insomnia [5].

The choice among these agents depends on insomnia phenotype (onset vs. maintenance vs. mixed), comorbid conditions, and insurance formulary. Patients with predominant sleep maintenance insomnia and prior zolpidem trials are the strongest candidates for a lemborexant PA approval in Massachusetts.

Practical Steps to Minimize Cost at a Massachusetts Pharmacy

Getting the lowest possible price on Dayvigo at a Massachusetts pharmacy requires checking several sources before the first fill.

Call the specific pharmacy location (not just the chain headquarters) and ask for the cash price on lemborexant 5 mg or 10 mg before presenting any discount card. Prices vary by location even within the same chain. Present GoodRx, RxSaver, or SingleCare discount codes and compare the resulting price against your insurance copay. The lower figure applies.

Patients with commercial coverage should apply the Eisai savings card online before the pharmacy visit and present the card alongside the insurance card. The pharmacist runs the claim through insurance first, then the savings card covers residual cost-sharing up to the program maximum.

For patients pursuing the MassHealth PA route, ask the prescribing clinician to submit the PA the same day the prescription is written so the review clock starts immediately. MassHealth has a 72-hour standard review timeline and a 24-hour urgent review option for clinically urgent cases [4].

If the first pharmacy's cash price exceeds the GoodRx estimate, ask the pharmacist to process the claim through the GoodRx BIN/PCN numbers printed on the discount card. This is a legitimate process; the pharmacist runs it as a cash transaction through GoodRx's contracted rate rather than through insurance.

Splitting a 10 mg tablet to achieve a 5 mg dose is not recommended because Dayvigo tablets are film-coated and Eisai does not label them as scorable, which introduces dose variability [2].

Side Effect and Safety Considerations Relevant to Cost Decisions

Choosing between the 5 mg and 10 mg dose affects both cost and side effect exposure. The 10 mg dose produces greater efficacy on sleep onset and maintenance endpoints but carries a higher rate of next-morning somnolence (reported in approximately 7 percent of patients in SUNRISE-1 versus 5 percent for 5 mg) [3]. Starting at 5 mg and titrating based on response minimizes unnecessary exposure.

The FDA requires the Dayvigo label to note that next-day psychomotor impairment may persist in some individuals, particularly women, who exhibit higher lemborexant plasma concentrations at a given dose due to lower average body weight and slower clearance [2]. This consideration may influence the treating clinician's dose selection and should be part of the telehealth evaluation.

Lemborexant is a Schedule IV controlled substance under the DEA, placing it in the same scheduling category as benzodiazepines and other benzodiazepine receptor agonists. Massachusetts pharmacies must dispense it with a valid controlled substance prescription; electronic prescriptions are required under state EPCS law.

Drug interactions are modest but clinically relevant. CYP3A4 inhibitors (clarithromycin, fluconazole, ritonavir) increase lemborexant exposure and should prompt consideration of dose reduction to 5 mg. CYP3A4 inducers (rifampin, carbamazepine) may reduce efficacy [2]. The FDA label recommends avoiding lemborexant in patients with severe hepatic impairment and using the 5 mg dose in those with moderate hepatic impairment [2].

What Massachusetts Residents Should Know About 2026 Formulary Changes

Pharmacy benefit formularies reset every January 1 and sometimes mid-year. Patients who had Dayvigo covered in 2025 should verify their 2026 formulary placement during open enrollment or immediately after January 1, 2026. Tier changes and new PA requirements can take effect without direct patient notification beyond the Summary of Benefits and Coverage document.

The Inflation Reduction Act's drug pricing provisions, which began affecting Medicare Part D in 2026, do not directly cap the cost of Dayvigo because lemborexant has not been selected for Medicare price negotiation as of this writing. However, the $2,000 annual out-of-pocket cap for Medicare Part D that took effect in 2025 benefits Massachusetts Medicare enrollees who require multiple brand-name medications [10].

Commercial plans in Massachusetts are subject to the state's Equitable Formulary Access law, which requires that non-preferred tier placement of a brand-name drug cannot result in patient cost-sharing that exceeds the cost-sharing that would apply to a therapeutically equivalent preferred brand by more than a specific multiplier. Patients who believe their insurer has violated this provision can file a complaint with the Massachusetts Division of Insurance [17].

Lemborexant prescriptions for adults aged 65 and older require the same DEA Schedule IV handling as for younger adults, but prescribers should document careful benefit-risk assessment in older patients per Beers Criteria recommendations, which flag orexin receptor antagonists as potentially inappropriate in older adults due to next-morning impairment risk [18].